The short version of growth hormone fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-22. Anything still debated is marked as such rather than presented as settled.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
History of environmental chemistry – history of the scientific study of the chemical and biochemical phenomena that occur in natural places. History of immunochemistry – history of the branch of chemistry that involves the study of the reactions and components of the immune system. History of medicinal chemistry – history of the discipline at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties, where they are involved with design, chemical synthesis and development for market of pharmaceutical agents (drugs). History of natural product chemistry – history of the scientific study of chemical compounds or substances produced by living organisms—history of chemical compounds found in nature that usually have a pharmacological or biological activity for use in pharmaceutical drug discovery and drug design. History of neurochemistry – history of the specific study of neurochemicals, which include neurotransmitters and other molecules such as neuro-active drugs that influence neuron function. History of computational chemistry – history of the branch of chemistry that uses principles of computer science to assist in solving chemical problems. History of chemo-informatics – history of the use of computer and informational techniques, applied to a range of problems in the field of chemistry. History of molecular mechanics – history of the uses of Newtonian mechanics to model molecular systems. History of flavor chemistry – history of the use of chemistry to engineer artificial and natural flavors.
== Treatment == Some strains of H. influenzae produce beta-lactamases, and are also able to modify its penicillin-binding proteins, so the bacteria have gained resistance to the penicillin family of antibiotics. In severe cases, cefotaxime and ceftriaxone delivered directly into the bloodstream are the elected antibiotics, and, for the less severe cases, an association of ampicillin and sulbactam, cephalosporins of the second and third generation, or fluoroquinolones are preferred. (Fluoroquinolone-resistant strains of H. influenzae have been observed). Macrolides and fluoroquinolones have activity against non-typeable H. influenzae and could be used in patients with a history of allergy to beta-lactam antibiotics. However, macrolide resistance has also been observed.
== History == The earliest fully documented case of aortic dissection is attributed to Frank Nicholls in his autopsy report of King George II of Great Britain, who had been found dead on 25 October 1760; the report describes a dissection of the aortic arch and into the pericardium. The term "aortic dissection" was introduced by the French physician J. P. Maunoir in 1802, and René Laennec labeled the condition "dissecting aneurysm". London cardiologist Thomas Bevill Peacock contributed to the understanding of the condition by publishing two series of the cases described in the literature so far: 19 cases in an 1843 review, and 80 in 1863. The characteristic symptom of tearing pain in the chest was recognized in 1855 when a case was diagnosed in life. Surgery for aortic dissection was first introduced and developed by Michael E. DeBakey, Denton Cooley, and Oscar Creech, cardiac surgeons associated with the Baylor College of Medicine, Houston, Texas, in 1954. DeBakey developed aortic dissection himself at age 97 in 2005, and underwent surgery in 2006. Endovascular treatment of aortic dissection was developed in the 1990s.
==== Medications ==== Following a heart attack, nitrates, when taken for two days, and ACE-inhibitors decrease the risk of death. Other medications include: Aspirin is continued indefinitely, as well as another antiplatelet agent such as clopidogrel or ticagrelor ("dual antiplatelet therapy" or DAPT) for up to twelve months. If someone has another medical condition that requires anticoagulation (e.g. with warfarin) this may need to be adjusted based on risk of further cardiac events as well as bleeding risk. In those who have had a stent, more than 12 months of clopidogrel plus aspirin does not affect the risk of death. Beta blocker therapy such as metoprolol or carvedilol is recommended to be started within 24 hours, provided there is no acute heart failure or heart block. The dose should be increased to the highest tolerated. Contrary to most guidelines, the use of beta blockers does not appear to affect the risk of death, possibly because other treatments for MI have improved. When beta blocker medication is given within the first 24–72 hours of a STEMI no lives are saved. However, 1 in 200 people were prevented from a repeat heart attack, and another 1 in 200 from having an abnormal heart rhythm. Additionally, for 1 in 91 the medication causes a temporary decrease in the heart's ability to pump blood. ACE inhibitor therapy should be started within 24 hours and continued indefinitely at the highest tolerated dose. This is provided there is no evidence of worsening kidney failure, high potassium, low blood pressure, or known narrowing of the renal arteries.
After a few warmup gigs throughout the Bay Area in 1969, Dawson, Nelson, and Torbert began to tour in May 1970 as part of a tripartite bill advertised as "An Evening with the Grateful Dead". An acoustic Grateful Dead set that often included contributions from Dawson and Nelson would then segue into New Riders and electric Dead sets, obviating the need to hire external opening acts. By the time the New Riders recorded their first album, there were several personnel changes. Hart temporarily left the Grateful Dead in February 1971. Although Hart contributed to two tracks on the album, former Jefferson Airplane drummer Spencer Dryden replaced him in the New Riders prior to his departure from the parent group. Dryden would remain with the group for ten years, ultimately serving as the band's manager. Their first album, eponymously titled was released on Columbia Records (under a contract informed by Clive Davis's long-term aspiration to sign the Grateful Dead) in late 1971. It proved to be a moderate success comparable to the Dead's releases of the era, peaking at No. 39 on the Billboard 200 chart. Entirely composed by Dawson (in comparison to the more egalitarian songwriting of later releases), the record was driven by Garcia's pedal-steel playing. With the New Riders desiring to become more of a self-sufficient group and Garcia needing to focus on his other responsibilities, the musician parted ways with the group in November 1971. Seasoned pedal steel player Buddy Cage was recruited from Ian and Sylvia's Great Speckled Bird to replace Garcia.
Sources: en.wikipedia.org
Retinol is chemically unstable in topical formulations and is sensitive to factors such as light, oxygen, heat, and heavy metals; formulation approaches including retinol derivatives, antioxidants, chelating agents, and lipid-based or nanoformulation systems have been investigated to improve stability, tolerability, and skin delivery. A common side effect of topical retinoid therapy is "retinoid dermatitis", irritation or reaction characterized by erythema, scaling, dryness, and pruritis. Topical retinol has been regulated as a cosmetic ingredient in the European Union and UK since November 2025; under Commission Regulation 2024/996, retinol was limited to a maximum of 0.05% retinol equivalent in body lotion and 0.3% in other leave-on and rinse-off products, with mandatory labelling.
The official position of West Germany concerning East Germany at the outset was that the West German government was the only democratically elected, and therefore the only legitimate, representative of the German people. According to the Hallstein Doctrine, any country (with the exception of the USSR) that recognised the authorities of the German Democratic Republic would not have diplomatic relations with West Germany. In the early 1970s, Willy Brandt's policy of "Neue Ostpolitik" led to a form of mutual recognition between East and West Germany. The Treaty of Moscow (August 1970), the Treaty of Warsaw (December 1970), the Four Power Agreement on Berlin (September 1971), the Transit Agreement (May 1972), and the Basic Treaty (December 1972) helped to normalise relations between East and West Germany and led to both German states joining the United Nations. The Hallstein Doctrine was relinquished, and West Germany ceased to claim an exclusive mandate for Germany as a whole. Following the Ostpolitik, the West German view was that East Germany was a de facto government within a single German nation and a de jure state organisation of parts of Germany outside the Federal Republic. The Federal Republic continued to maintain that it could not within its own structures recognise the GDR de jure as a sovereign state under international law; while at the same time acknowledging that, within the structures of international law, the GDR was an independent sovereign state.
==== Protoplasmic astrocytes ==== The protoplasmic astrocytes are the most prevalent and are found in grey matter tissue, possess a larger quantity of organelles, and exhibit short and highly branched tertiary processes.
A GFD involves removing all food and drink that contains wheat, rye, barley, and gluten derivatives. Coeliac disease symptoms can improve within days of adopting a GFD, and the diet improves quality of life, prevents further complications, and can normalise some effects of the disease such as stunted growth. The GFD can be difficult, requiring significant education and motivation. Additionally, the GFD diet may lead to nutritional deficiencies due to difficulties accessing nutritionally balanced gluten-free food. As such, a referral to a dietitian is recommended by treatment guidelines. A dietitian can help those with coeliac disease identify gluten-containing food and maintain a nutritionally balanced diet. The exact amount of gluten that may be tolerable for those with coeliac disease varies, with some people able to consume around 35 mg per day without damage to the intestines, while others can not tolerate more than 10 mg a day. Currently, international regulatory agencies require a product to contain less than 20 ppm (about 6 mg per day) of gluten to be labelled as gluten-free.
Sources: en.wikipedia.org
=== Genetic stability === In order for there to be genetic stability within a marijuana strain the breeder has to go through selection and breeding, pinpointing the dominant and recessive genes within the two strains being crossed. After analyzing offspring with the preferred traits a breeder is looking for, the breeder will select the preferred traits and continue to breed those offspring to create the desired final product. Selection is a crucial process for a breeder to create a strain, especially if a client is looking for something with specific plant traits the breeder has to ensure that the hybrid's genetic traits have been closed in enough so unwanted traits aren't expressed in future harvests.
gene regulation The broad range of mechanisms used by cells to control the activity of their genes, especially to allow, prohibit, increase, or decrease the production or expression of specific gene products, such as RNA or proteins. Gene regulation increases an organism's versatility and adaptability by allowing its cells to express different gene products when required by changes in its environment. In multicellular organisms, the regulation of gene expression also drives cellular differentiation and morphogenesis in the embryo, enabling the creation of a diverse array of cell types from the same genome.
On 12 October 1968, Kissinger told Allen that Harriman persuaded Johnson to order a bombing halt of North Vietnam. Allen called John Mitchell, Nixon's campaign manager, who agreed that this was most important information. As a reward, Mitchell told Allen that Kissinger would receive the senior post he craved, with Allen saying the office of National Security Advisor would suit Kissinger the best. At the same time, Kissinger was in contact with the Democratic candidate, Vice President Hubert Humphrey, lobbying for a senior post if Humphrey won the election. Kissinger had served as the foreign policy adviser to the Republican governor of New York, Nelson Rockefeller, during his failed bids to win the Republican nomination in the elections of 1960, 1964 and 1968. He had a low opinion of Nixon during this time, speaking of his "shallowness" and of his "dangerous misunderstanding" of foreign policy. Many were surprised when Kissinger accepted Nixon's offer to serve as his National Security Advisor. Nixon said of Kissinger: "I don't trust Henry, but I can use him".
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.